TheEdgeResearch
Home / Stocks / CPHRF

Cipher Pharmaceuticals Inc. (CPHRF)

OTC Healthcare Medical - Pharmaceuticals
$10.23 ▼ -20.08%
Market Cap
$259.8M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.48
52-Wk Range
8.92-15
CEO
Craig J. Mull
Country
CA
Currency
USD

Cipher Pharmaceuticals Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Mississauga, ON, CA. The stock last traded at $10.23, down 20.08% on the session, giving a market capitalisation of $259.8M. On trailing twelve-month figures it carries a trailing P/E of 8.36, a net margin of 60.8%. Its beta of 0.48 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
8.36
Price / Sales
5.09
Price / Book
1.94
EV / EBITDA
10.07
Gross margin
74.5%
Operating margin
38.8%
Net margin
60.8%
Return on equity
Debt / equity
0.00
Current ratio
1.25
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
6
IPO date
2006-02-02
Headquarters
Mississauga, ON, CA
About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. functions as a specialized pharmaceutical company based in Canada. The firm markets a diverse portfolio of therapies, including Epuris (CIP-ISOTRETINOIN), an isotretinoin formulation specifically developed for addressing severe acne; Ozenoxacin, prescribed for the management of impetigo in both adult and pediatric populations; Actikerall, indicated for treating palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream designed to diminish unwanted facial hair growth in women; BRINAVESS, a treatment aimed at restoring sinus rhythm in adults; and AGGRASTAT, an anti-platelet medication administered intravenously. Furthermore, Cipher holds licenses for several products, which encompass CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a fenofibrate-based formulation used to treat hyperlipidemia, a disorder characterized by high cholesterol; and Conzip/Durela (CIP-Tramadol), a tramadol formulation intended for alleviating moderate to moderately severe pain. Looking ahead, the company's development pipeline features several innovative compounds: Trevyent, a vasodilatory prostacyclin analogue targeting pulmonary arterial hypertension; CF-101, which is being explored for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for the treatment of onychomycosis; and DTR-001, a cream under development for tattoo removal. Cipher Pharmaceuticals Inc. was established in the year 2000, with its primary operations located in Oakville, Canada.

Comparable companies

Cipher Pharmaceuticals Inc. is most often compared with the following Healthcare names:

ABTIAONCBHCCFBHHKFHNSBFMAYNFNIKAPSIQTRGNFTSNLF
More research on CPHRF
CPHRF technical analysis CPHRF TheEdge Score Compare against peers
Open full interactive analysis & DCF →